Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation

PURPOSE: Dolutegravir (DTG) is primarily metabolized by UGT1A1 with CYP3A as a minor route. Carbamazepine (CBZ) is a potent inducer of these enzymes; thus, the effect of oral extended-release CBZ on DTG pharmacokinetics (PK) was evaluated to provide dose recommendation when co-administered. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Ivy, Weller, Steve, Patel, Juhin, Borland, Julie, Wynne, Brian, Choukour, Mike, Jerva, Fred, Piscitelli, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865535/
https://www.ncbi.nlm.nih.gov/pubmed/26898568
http://dx.doi.org/10.1007/s00228-016-2020-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865535/
https://www.ncbi.nlm.nih.gov/pubmed/26898568
http://dx.doi.org/10.1007/s00228-016-2020-6

Ejemplares similares